Because Patients Are Diverse,
Preclinical Models Should Be Too.
Bringing Precision Medicine to Preclinical Drug Development
Patented Technology • Animal-Free • Human Biological Diversity • AI-Enabled
The Cell Educating Technology™
PredictCan’s patented Cell Educating Technology™ harnesses the remarkable plasticity of human cell lines.
The Challenge
Human Diversity Is the Missing Dimension of Drug Development
Every patient is biologically unique. Metabolism, immune status, age, sex, ethnicity, lifestyle, and environmental factors all influence how individuals respond to therapy. While some patients experience life-changing benefits, others may show little response or develop serious adverse effects.
Despite this reality, most preclinical models are built around a single biological profile, limiting their ability to predict clinical outcomes.
The Solution
Individual-centric Models, Built From Human Diversity
PredictCan brings human biological diversity into preclinical research by generating personalized phenotypic models that capture interindividual variability at scale. This enables pharmaceutical researchers to evaluate efficacy and safety across representative human populations before clinical trials begin.
Moving beyond the traditional question:
"Does This Drug Work?"
PredictCan helps answer the questions that truly matter:
• Who Will Benefit ?
• Who Is At Risk ?
• How Do Responses Vary Across Populations ?
• Why Do These Differences Occur?
Why PredictCan ?
Human-relevant biology without compromising scalability
PredictCan combines the biological relevance and diversity of human-derived models with the robustness, reproducibility, and scalability required for industrial drug development.
Human Biological Diversity
Replicates interindividual biological variability through individualized human models. Build representative cohorts to capture differences in drug response across diverse biological backgrounds.
Reproducible
Data
Combines human biological diversity with standardized experimental conditions. Delivers robust and reproducible results across independent experiments while preserving meaningful interindividual differences in drug response.
Scalable
Platform
Designed to bring human diversity to scale. Enables parallel testing across multiple individuals, compounds, doses, and conditions, making population-level human studies compatible with preclinical drug development workflows.
Animal-Free
Platform
A human-based platform designed to generate decision-relevant data without relying on animal biology. Supports the transition toward New Approach Methodologies (NAMs) for more human-relevant preclinical drug development.
Preclinical Precision Medicine
Bring patient diversity into drug development before clinical trials begin. Reveal differences in efficacy and toxicity across individuals, identify susceptible or responsive populations, and support better-informed preclinical decisions.
Applications
Predicting Safety And Efficacy Across Human Diversity
Two questions define every drug development program: is it safe? Does it work? PredictCan answers both by modeling the individual, not the average patient.
Drug Safety
Comparative mechanistic study of DILI using matched susceptible and non-susceptible donor models — identifying the cell populations and molecular pathways that initiate liver injury.
Drug Efficacy
Responder and non-responder profiling across individualized models, revealing population-level response patterns before they show up in the clinic.
Work With Us
Partner with PredictCan
Whether you need a study run, a technology co-developed, or a platform implemented in-house — there’s a way to work with us that fits.
Outsourced
Services
"We do it for you."
Access PredictCan’s platforms and expertise for your development program — from candidate evaluation to mechanistic investigation.
Co-developed
Collaboration
"We develop it with you."
Combine our technology with your expertise to build new organ- or disease-specific models, AI tools, or biomarker programs.
In-house
Tech Transfer
"You implement it with us."
Bring PredictCan’s technology and know-how into your own laboratory, with training and implementation support.
News
A serum-derived 3D tumor model platform for personalized prediction and monitoring of chemotherapeutic response in pancreatic ductal adenocarcinoma
AI-enhanced clinical trial-in-a-dish platform for improved DILI risk classification and mechanistic insights into hepatotoxicity
A new in vitro rat liver platform capturing biological diversity for drug-induced liver injury assessment and reduction of animal use in drug discovery and development
PredictCan Presents Its DILI Platform at the 3RsC & IQ Consortium Liver MPS Webinar
New Study Introduces an Individual-Centric In Vitro–In Vivo Strategy for DILI Assessment
